Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 topical JB991 dose-ranging trial in plaque psoriasis
2006-002523-16Phase 2Completed
- Sponsor
- Synphora AB
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of JB991 in plaque psoriasis (4 arms), sponsored by Synphora AB. Primary endpoints: Within-patient difference in Psoriasis Severity Index sum score for JB991 750 µg/g versus placebo after 8 weeks, Within-patient difference in Psoriasis Severity Index sum score for JB991 30 µg/g versus placebo after 8 weeks and 3 more. Started Aug 2006; status: completed.
02
Drugs
JB991
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2006-002523-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002523-16.